International Clinical Trial: A Single-Arm, Single-Center, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination with Gemcitabine for Advanced Driver Gene-Negative Squamous Non-Small Cell Lung Cancer with Disease Progression Following PD-(L)1 Inhibitor Therapy

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120009) titled 'A Single-Arm, Single-Center, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination with Gemcitabine for Advanced Driver Gene-Negative Squamous Non-Small Cell Lung Cancer with Disease Progression Following PD-(L)1 Inhibitor Therapy' on March 7.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital)

Condition: Non-small cell lung cancer

Intervention: Single Arm:Apatinib 5mg/kg intravenous infusion (30-60 minutes), once every 21 days until disease progression, in...